Beam Therapeutics (MEX:BEAM) Tax Expense: MXN0 Mil (TTM As of Mar. 2026)


MEX:BEAM Beam Therapeutics Inc MEX:BEAM
66 GF Score
Price MXN628.46
GF Value MXN528.66
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Beam Therapeutics Tax Expense?

Beam Therapeutics MEX:BEAM 66 Tax Expense is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 66/100 and a GF Value™ of MXN528.66 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Beam Therapeutics's tax expense for the months ended in Mar. 2026 was MXN0 Mil. Its tax expense for the trailing twelve months (TTM) ended in Mar. 2026 was MXN0 Mil.


Beam Therapeutics  (MEX:BEAM) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Beam Therapeutics Tax Expense Related Terms


Beam Therapeutics Tax Expense Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Tax Expense Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Expense
Get a 7-Day Free Trial Premium Member Only 0.00 66.48 23.19 0.81 0.00

Beam Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:BEAM
66GF Score
Beam Therapeutics Inc MEX:BEAM
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of MXN0 Mil mean?
Beam Therapeutics (MEX:BEAM) has a Tax Expense of MXN0 Mil as of Mar. 2026. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' Tax Expense too high?
Beam Therapeutics' current Tax Expense is MXN0 Mil. Overall, Beam Therapeutics has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Tax Expense compare to ELVN and IDYA?
Beam Therapeutics' Tax Expense of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Biotechnology company?
A good Tax Expense depends on the Biotechnology industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Tax Expense is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN528.66, compared to a current price of MXN628.46 — trading 18.9% above its estimated fair value. The current Tax Expense is MXN0 Mil. Beam Therapeutics' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Tax Expense is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN628.46 is trading 18.9% above its estimated GF Value™ of MXN528.66. GuruFocus considers Beam Therapeutics to be Modestly Overvalued.

Key valuation signals for MEX:BEAM:

  • Tax Expense: MXN0 Mil
  • GF Value™: MXN528.66 vs. price of MXN628.46 (18.9% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
66GF Score

Get the complete analysis for MEX:BEAM

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN628.46
Price
MXN528.66
GF Value